EUROPE’S PARTNERSHIP FOR HEALTH

Innovative Medicines Initiative
Introducing IMI

The Innovative Medicines Initiative (IMI) is a partnership between the European Union (EU), represented by the European Commission, and the European pharmaceutical industry, represented by the European Federation of Pharmaceutical Industries and Associations (EFPIA).

IMI is working to improve health by speeding up the development of, and patient access to, the next generation of medicines, particularly in areas of unmet medical or social need.

IMI does this by facilitating collaboration between the key players in health research, including universities, pharmaceutical companies, small and medium-sized enterprises (SMEs), patient organisations, and others.

IMI has a total budget of over €5 billion for the period 2008-2024. Half of this comes from the EU’s research and innovation programmes, while the other half comes from EFPIA members as well as some other large organisations and companies.
**Tackling the scourge of antimicrobial resistance:** The TRANSLOCATION project has worked out the structure of proteins involved in transporting substances (including, potentially antibiotics) into and out of bacterial cells.

**Better clinical trials for Alzheimer’s disease:** The EPAD project is pioneering a novel, more flexible approach to clinical trials of drugs designed to prevent Alzheimer’s dementia. The ‘adaptive’ trial design should deliver better results faster and at lower cost.

**New tools to study diabetes:** In a world first, the IMIDIA project developed the world’s first functional line of human pancreatic beta cells (the cells which go wrong in diabetes). These make it easier for scientists to study diabetes in the lab.
Towards safer medicines: The WEB-RADR project has developed a smartphone app that allows patients, carers and healthcare professionals to quickly and easily report side effects of medicines.

Faster drug development: The European Lead Factory has created a unique drug discovery platform that scientists can apply to use for their own research. Users report that the results have significantly accelerated their drug development programmes.

Promoting patient involvement in research: The EUPATI project has compiled an online, multilingual educational toolbox (www.eupati.eu) for patients who want to know more about, or get involved in, medicines research and development.
The IMI community

- 970 academic / research organisation teams
- 552 EFPIA teams
- 202 SME teams
- 31 patient organisation teams
- 108 other teams

- 2 300 JOBS
- 1 749 PUBLICATIONS
- 20 PATENT APPLICATIONS
- 13 SPIN-OFFS
What disease and research areas does IMI support?

Health priorities in the IMI Strategic Research Agenda 2014:
- antimicrobial resistance
- osteoarthritis
- cardiovascular diseases
- diabetes
- neurodegenerative diseases
- psychiatric diseases
Infectious diseases

Brain disorders

Metabolic disorders

Stem cells

Cancer

Biologicals

Vaccines

Lung diseases

Drug delivery

Drug kinetics

Search Agenda 2014

- respiratory diseases
- immune-mediated diseases
- ageing-associated diseases
- cancer
- rare/orphan diseases
- vaccines
Get involved

IMI regularly issues new Calls for proposals, giving researchers from diverse sectors the opportunity to apply to participate in ambitious projects that will pave the way for the development of the medicines of the future.

Simon Lovestone
Professor of Translational Neuroscience
University of Oxford, UK

IMI has really made a change to the way we do our work. Of course it brings an important funding stream but more importantly than that, it brings collaborations with industry. Working with industry colleagues we have gained an incredible amount – ranging from technical expertise, to compounds and reagents to project management with milestone driven programmes.

Dimitrios Tzalis
Founder and Chief Executive Officer of Taros Chemicals, Dortmund, Germany
Head of the European Lead Factory Chemistry Consortium

As an SME, participation in IMI’s European Lead Factory project has given us excellent scientific insights and the opportunity to build long-lasting relationships and networks, as well as the opportunity to enhance our skills in areas like people management and consensus building. Furthermore, as an SME with a strong focus on innovation, working with IMI has given extra momentum to our broader activities.
Breda Flood  
*President of the European Federation of Allergy and Airways Diseases Patients’ Associations*

Participating in IMI projects allows patients to make a very real contribution to research on diseases that affect them. As a partner in the U-BIOPRED project on severe asthma, my voice as a patient was listened to from the outset and patient input proved instrumental in helping the project achieve its goals.

Carlo Incerti  
*Head of Global Medical Affairs, Genzyme*  
*Member of the IMI Governing Board*

IMI has revolutionised the way companies are working on major R&D programs. Where before there were firewalls and diffidence, now we have cross-company teams who are working to address major unmet medical needs.

Carlos Moedas  
*Commissioner for Science, Research and Innovation*  
*European Commission*

Unlocking the potential of public funding is a priority for the European Commission. IMI is one of our biggest success stories. This public-private partnership combines research, technology, innovation and entrepreneurship to speed up the development of treatments against disease and to address the health needs of citizens.